A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

← catalyst calendar

NCT05675449

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

59actual

Sites

Countries

Israel, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-12-14

actual

When the study began enrolling

Primary completion

2026-03-11

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-02-29

estimated

The whole study's end, after follow-up

First posted

2023-01-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Multiple Myeloma

Interventions

Drug: Elranatamab — also filed as PF-06863135
Drug: Carfilzomib — also filed as Kyprolis
Drug: Maplirpacept — also filed as PF-07901801, TTI-622

Primary outcomes

what the primary-completion date above is the date OF

Part 1 Number of participants with dose limiting toxicity (DLT)

measured From first dose of elranatamab through the end of the first cycle of combination treatment, about 42 days.

Part 2A Number of participants with dose limiting toxicity

measured From the first dose of maplirpacept through the first cycle of combination treatment, about 64 days.

Part 2B Number of participants with dose limiting Toxicity

measured From first dose of elranatamab through the first cycle of combination treatment, about 42 days.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed